Efficacy and Safety of Vorapaxar as Approved for Clinical Use in the United States

BACKGROUND: Vorapaxar is a protease‐activated receptor‐1 antagonist approved by the U.S. Food and Drug Administration (FDA) for the reduction of thrombotic cardiovascular (CV) events in patients with a history of myocardial infarction (MI) and peripheral artery disease (PAD), without a previous stro...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Am Heart Assoc
Main Authors: Magnani, Giulia, Bonaca, Marc P., Braunwald, Eugene, Dalby, Anthony J., Fox, Keith A. A., Murphy, Sabina A., Nicolau, José Carlos, Oude Ophuis, Ton, Scirica, Benjamin M., Spinar, Jindrich, Theroux, Pierre, Morrow, David A.
Formato: Artigo
Idioma:Inglês
Publicado em: Blackwell Publishing Ltd 2015
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4392433/
https://ncbi.nlm.nih.gov/pubmed/25792124
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.114.001505
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados